Literature DB >> 34697097

Metronidazole-induced neurotoxicity.

Danica Quickfall1, Nick Daneman1, Adam A Dmytriw1, David N Juurlink2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34697097      PMCID: PMC8562982          DOI: 10.1503/cmaj.201671

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.

Metronidazole-induced neurotoxicity is underappreciated

Metronidazole, usually prescribed for anaerobic and protozoal infections, can uncommonly cause adverse effects involving the central nervous system. The exact mechanism is unclear. In 1 case–control study, the incidence of neurologic events was 0.25%, although this is likely an underestimate.1

Metronidazole-induced neurotoxicity can present with a variety of clinical syndromes

Common central nervous system features include ataxia, dysarthria and altered mental status, but rarer manifestations such as seizures, encephalopathy and cerebellar dysfunction have also been described.2 Peripheral neuropathy manifests as diminished sensation, numbness and neuropathic pain. Patients with central nervous system abnormalities have coexisting peripheral neuropathy in roughly one-third of cases.2

Dose and duration of treatment are the primary risk factors, but symptoms may appear early and with small doses

Case reports suggest the average duration of treatment before symptom onset is 6–7 weeks, but symptoms can appear within days of initiation.2,3 Patients receiving metronidazole for inflammatory bowel disease, osteomyelitis and large, undrained abscesses are at greatest risk of neurotoxicity due to long exposure. A review of 110 adult cases with metronidazole-induced encephalopathy found the median cumulative dose was 65.4 g, although there was wide variability (range 5–2000 g).2

Up to 90% of patients with central nervous system involvement have characteristic lesions on magnetic resonance imaging (MRI)

Typical radiologic findings are most commonly seen on T2-weighted fluid-attenuated inversion recovery (FLAIR) MRI sequences. Symmetric, hyper-intense lesions of the dentate nuclei are commonly present, with lesions of the callosal splenium and dorsal pons of the same signal characteristics being the next most common abnormalities.2,4

Discontinuing metronidazole usually results in improvement

Most patients experience complete symptom resolution upon cessation of metronidazole, and complete or near-complete radiologic resolution occurs in about 75% of cases.2,4 The time course varies, but the symptoms of most patients resolve within 2 weeks.4 CMAJ invites submissions to “Five things to know about …” Submit manuscripts online at http://mc.manuscriptcentral.com/cmaj
  4 in total

1.  Metronidazole-induced encephalopathy: a systematic review.

Authors:  Caspar Godthaab Sørensen; William Kristian Karlsson; Faisal Mohammad Amin; Mette Lindelof
Journal:  J Neurol       Date:  2018-12-07       Impact factor: 4.849

2.  Acute metronidazole-induced neurotoxicity: an update on MRI findings.

Authors:  L Patel; P Batchala; R Almardawi; R Morales; P Raghavan
Journal:  Clin Radiol       Date:  2019-12-16       Impact factor: 2.350

Review 3.  Metronidazole-induced central nervous system toxicity: a systematic review.

Authors:  Akira Kuriyama; Jeffrey L Jackson; Asako Doi; Toru Kamiya
Journal:  Clin Neuropharmacol       Date:  2011 Nov-Dec       Impact factor: 1.592

4.  Metronidazole-associated Neurologic Events: A Nested Case-control Study.

Authors:  Nick Daneman; Yi Cheng; Tara Gomes; Jun Guan; Muhammad M Mamdani; Farah E Saxena; David N Juurlink
Journal:  Clin Infect Dis       Date:  2021-06-15       Impact factor: 9.079

  4 in total
  2 in total

1.  Identifying Acute Neuropsychiatric Events in Children and Adolescents.

Authors:  James W Antoon; James A Feinstein; Carlos G Grijalva; Yuwei Zhu; Emily Dickinson; Justine C Stassun; Jakobi A Johnson; Mert Sekmen; Yasas C Tanguturi; James C Gay; Derek J Williams
Journal:  Hosp Pediatr       Date:  2022-05-01

2.  Exacerbation of Mania due to Metronidazole in a Bipolar Disorder Patient.

Authors:  Majed AlShakori; Savera I Arain; Shabeer A Thorakkattil; Syed Abdulkader
Journal:  Case Rep Psychiatry       Date:  2022-06-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.